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Background: Some patients with COPD may share characteristics of asthma; this is the 
so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria 
for ACOS, and most treatments for asthma and COPD have not been adequately tested in this 
population.
Materials and methods: We performed a survey among pulmonology specialists in asthma and 
COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case 
scenarios of ACOS patients. The participants answered a structured questionnaire and attended 
a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS.
Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey 
(13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of 
ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addi-
tion, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most 
frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant 
smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced 
vital capacity ,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum 
(80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years 
of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination 
of a long-acting β
2
-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple 
therapy) for severe ACOS.
Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the 
diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully 
reversible airflow limitation are considered the main characteristics of ACOS, with the most 
accepted first-line treatment being long-acting β
2
-agonist/inhaled corticosteroids.
Keywords: asthma, COPD, ACOS, survey, guidelines
Introduction
Asthma and COPD are two of the most important public health care problems, due to 
their elevated prevalence and high socioeconomic cost.1–4 Although COPD and bron-
chial asthma are chronic inflammatory diseases affecting the airway and essentially 
characterized by the presence of bronchial obstruction, they are separate nosological 
entities with different etiopathogenic bases, diagnostics, and therapeutic and prognostic 
characteristics.5
Nonetheless, these two diseases may coexist. The mixed asthma–COPD phenotype 
(asthma–COPD overlap syndrome [ACOS]) has been defined as symptoms of increased 
variability of airflow in association with incompletely reversible airflow obstruction.6 
These patients are of special interest, since they are usually excluded from clinical 
trials with medications and also represent a clinically very important population with 
particular characteristics: more respiratory symptoms, more frequent exacerbations, 
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and worse health-related quality of life.7,8 They are also 
characterized by an increase in comorbidity9 and a greater 
consumption of health care resources compared with patients 
with only asthma or COPD.10
The frequency of ACOS in patients with COPD ranges 
from 10% to 55% according to the type of population studies, 
and particularly the diagnostic criteria applied. In the epide-
miological EPI-SCAN study, 17% of subjects with COPD 
were classified as ACOS.8 In another study, Soriano et al11 
estimated that approximately 23% of patients with COPD 
50–59 years of age could have ACOS, with this value rising 
to 52% in subjects 70–79 years of age.
There are currently no universally accepted, validated 
criteria for the diagnosis of ACOS. The Spanish consensus 
document on ACOS in COPD was published in 2012,12 and 
included the consensus of a series of diagnostic criteria that 
were later adopted in part or modified by the Spanish guide-
lines for COPD,13 as well as other national guidelines.14,15 The 
recent publication of the GINA (Global Initiative for Asthma) 
and GOLD (Global initiative for chronic Obstructive Lung 
Disease) guidelines in 2014 also included recommendations 
for the identification of these patients.16
Although different studies recognize the presence of 
ACOS, the detection, diagnosis, and treatment of these 
patients in clinical practice is not always simple and involves 
different interpretations. In this context, following the pub-
lication of the Spanish consensus on ACOS and in light of 
the new GINA and GOLD guidelines, the aim of the present 
study was to determine the opinion of Spanish pulmonolo-
gists who are experts in COPD or asthma in relation to 
ACOS in clinical practice and know what they consider to 
be the diagnostic criteria and management strategies to be 
undertaken in these patients. For this study, a representative 
sample of specialists in asthma and COPD from all regions 
of Spain were invited to participate.
Materials and methods
A process of debate was carried out in two phases in a 
group of pulmonologists who are specialists in asthma or 
COPD. The participating physicians were selected based 
on their participation in the Spanish working groups and 
in the Spanish guidelines of asthma or COPD. In the first 
phase, the participants were sent a structured questionnaire 
developed by two coordinators of the study (MM and VP), 
which was composed of 22 items on the profile of the spe-
cialists and their opinion on different aspects of ACOS: 
epidemiology, diagnosis, and treatment. The data obtained 
in the questionnaire were analyzed by means of descriptive 
statistics (percentages and mean values) before undergoing 
the second phase in order to have, a priori, some orientation 
as to the opinion of the participants in the debate.
In the second phase, a work meeting was held following 
the methodology of brainstorming based on the Metaplan® 
technique.17 This technique allows for structuring the knowl-
edge of the attendees, who write their answers on cards. 
A facilitator then presents each card to the group and moderates 
the debate generated. The main advantages compared to a con-
ventional meeting are that it promotes equal participation of all 
the attendees and facilitates an orderly debate, which in turn 
allows the determination of points of consensus and dissent.
The participants gave their opinion and orderly debate about 
the aspects included in the questionnaire in the first phase:
•	 The new definition of patients with ACOS provided by the 
GINA–GOLD guidelines:16 ACOS is defined by a limi-
tation of airflow with different characteristics generally 
associated with asthma and COPD. ACOS is therefore 
identified with characteristics shared by the two diseases 
asthma and COPD.
•	 The definition of ACOS proposed by a Spanish consensus 
group:12 the diagnosis is made when two major criteria or 
one major and two minor criteria are met. The major cri-
teria include a very positive bronchodilator test (increase 
in forced expiratory volume in 1 second [FEV
1
] $15% 
and $400 mL), eosinophilia in sputum, and personal history 
of asthma. Minor criteria include high total IgE, personal 
history of atopy, and positive bronchodilator test (increase in 
FEV
1
 $12% and $200 mL) on two or more occasions.
•	 The diagnostic criteria that the participants consider should 
be taken into account in these patients. These criteria were 
classified according to their clinical relevance and applica-
bility in respiratory clinics and primary care practices.
•	 The treatment to use, according to the presentation 
of three clinical situations of patients with a possible 
diagnosis of ACOS.
•	 Future actions to be carried out to consolidate the concept 
of ACOS.
statistical analysis
For analysis of the answers to the questionnaire, the cat-
egorical variables are expressed as absolute frequencies and 
percentages, and the quantitative variables are expressed as 
mean, median, and minimum and maximum standard devia-
tion. To analyze the data obtained in the debate session, the 
answers were transferred to an Office Excel calculation sheet 
(Microsoft Corporation, Redmond, WA, USA), calculating 
the percentage of votes for each of the blocks established by 
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grouping the main ideas developed in the meeting. Statistical 
analysis was performed with SPSS version 17.0 (SPSS Inc, 
Chicago, IL, USA).
Results
A total of 26 pulmonologists participated in the study: 13 
specialists in asthma and 13 in COPD. Of these, 20 (77%) 
were men and six women (23%), with a mean age of 49.7 years 
(standard deviation 7.4 years).
Phase 1: predebate questionnaire
All the participants answered the questionnaire from 2 weeks 
to 2 months before the meeting. Responses obtained are 
presented in Table 1. Among the most relevant results, it was 
of note that 84.6% of the participants agreed in recognizing 
ACOS and declared that a mean of 12.6% (standard deviation 
7.0%) of COPD patients attended in their office presented 
with a combination of asthma and COPD. According to 
80.8% of the participants, the diagnostic criteria for ACOS 
Table 1 responses to the questionnaire about aCOs administered before the debate
Epidemiology n (%)
Of all the patients you see, give an approximation of the percentage with aCOs (mean [sD]) 12.6 (7.0)
Do some patients have a mixed asthma–COPD phenotype? Yes 22 (84.6)
Diagnosis
Are the diagnostic criteria of ACOS well defined? Yes 5 (19.2)
regarding the debate on the possible coexistence of asthma and COPD in the same patient, do you think it is:
Unnecessary. They do not coexist. 0
Inadmissible. This is an academic more than a practical question. In the end, the patients receive the same treatment. 1 (3.8)
Futile. The opinions among professionals are very conflicting, irreconcilable. 1 (3.8)
Admissible, but it is not well defined. 8 (30.8)
Essential. The experts should reach some agreement. It could have specific future therapeutic consequences. 16 (61.5)
In your opinion, the combination of criteria of asthma and COPD in the same patient is:
A specific phenotype of a disease. These are patients with COPD who have a history and criteria of allergic asthma. 8 (30.8)
a coincidence of the two diseases in the same patient. It is the overlapping of two prevalent diseases, not the phenotype 
of one of these diseases.
14 (53.8)
an invention. This does not exist. One disease always predominates another. The other characteristics act as diagnostic 
confounders.
2 (7.7)
none of the above. 2 (7.7)
What is your opinion of the aCOs criteria of the spanish consensus? (multiple choice: more than one answer allowed)
They are adequate. 1 (3.8)
They are too complex. 9 (34.6)
They should be validated. 20 (76.9)
They are incomplete. 7 (26.9)
They are too many. 2 (7.7)
To what degree do you agree with the definition and diagnostic criteria of ACOS drawn up in the Spanish consensus?
I fully agree. 0
Partially, but in the main I agree. 9 (34.6)
Mid-position between agreement and disagreement. 8 (30.8)
Partially, but in the main I disagree. 6 (23.1)
I completely disagree. 3 (11.5)
I have no definite opinion. 0
should there be main, major, and minor diagnostic criteria for aCOs?
Yes. 9 (34.6)
no. 5 (19.2)
I don’t know. 12 (46.2)
Which of the following criteria of aCOs do you consider to be adequate? (multiple choice: more than one answer allowed)
Very positive bronchodilator test. 13 (50.0)
at least two positive bronchodilator tests. 9 (34.6)
elevated Ige. 11 (42.3)
history of atopy. 14 (53.8)
Previous history of asthma. 23 (88.5)
history of smoking. 19 (73.1)
Postbronchodilator FeV1/FVC ,0.7 18 (69.2)
elevated FenO. 14 (53.8)
eosinophilia in sputum. 12 (46.2)
eosinophilia in blood. 11 (42.3)
(Continued)
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Table 1 (Continued)
The diagnostic evaluation of the asthma component of aCOs in the spanish consensus is:
Perfect, and well adjusted to the phenotype. 0
Partial, but sufficient for clinical practice. 7 (26.9)
Insufficient, since it does not include patients with nonallergic asthma. 15 (57.7)
Inadmissible, as there is no such phenotype. 3 (11.5)
Diagnostic evaluation of the asthma component of aCOs in the spanish consensus should be:
eliminated. There is no mixed asthma–COPD phenotype. 1 (3.8)
Redefined in depth, including patients with nonallergic asthma. 16 (61.5)
Partially modified, perhaps being simplified. 9 (34.6)
Fully maintained as defined by the consensus of experts. 0
The role of smoking in the pathogenesis of the combination of asthma and COPD in the same patient:
Is irrelevant. The symptoms and pulmonary function are important. 0
Is overevaluated. These patients may exist without having previously smoked. requiring the presence of smoking 
undeservedly excludes patients with the syndrome.
3 (11.5)
Important, since it actually involves smoker or ex-smoker asthma patients. 18 (69.2)
Is essential. This phenomenon cannot exist without its presence or history. 5 (19.2)
Do you think the aCOs criteria of the spanish consensus have contributed to the diffusion of the mixed asthma–COPD 
phenotype? Yes
21 (80.8)
Can aCOs change over time?
Yes. 14 (53.8)
no. 4 (15.4)
I don’t know. 8 (30.8)
Treatment
Does aCOs require differentiated treatment? Yes 23 (88.5)
From the following, select the first choice of pharmacological treatment for a patient with severe poorly controlled asthma 
and chronic airflow obstruction.
Combination of laBa/ICs + montelukast. 6 (23.1)
Combination of laBa/ICs + laMa. 16 (61.5)
Combination of laBa/ICs + theophylline. 1 (3.8)
Combination of laBa/ICs + omalizumab. 3 (11.5)
From the following, select the first choice of pharmacological treatment for a patient with very severe ACOS.
Combination of laBa/ICs + montelukast. 1 (3.8)
Combination of laBa/ICs + laMa. 25 (96.2)
Combination of laBa/ICs + theophylline. 0
Combination of laBa/ICs + roflumilast. 0
The commercial impact of the new bronchodilators for COPD and the greater risk of respiratory infections associated 
with inhaled steroids may make anti-inflammatory treatment in ACOS patients:
absolutely underused, particularly in primary care. 1 (3.8)
less used than it should be on being consigned to the characteristic treatment of COPD. 12 (46.2)
Minor. There is a great tradition of prescribing laBa + ICs in severe COPD. 8 (30.8)
null. ICs continue to be the treatment of choice in asthma as well as aCOs. 5 (19.2)
Therapeutic management by specialties (pulmonology/primary care)
should the criteria of aCOs be different for pulmonology and primary care?
Yes. 3 (11.5)
no. 19 (73.1)
I don’t know. 4 (15.4)
appropriate diagnostic and therapeutic evaluation of patients with aCOs should:
always be done by a primary care physician. 0
always be done by a pulmonologist. 7 (26.9)
Be done according to the severity of the patient, with mild cases evaluated by primary care physicians and severe cases 
by pulmonologists.
6 (23.1)
Be done according to the quality of care and resources available in primary care of a determined health care area. If 
these are low, it should be done by a pulmonologist.
13 (50.0)
I don’t know. 0
Abbreviations: aCOs, asthma–COPD overlap syndrome; sD, standard deviation; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FenO, fraction 
of exhaled nitric oxide in exhaled air; laBa, long-acting β2-agonist; ICs, inhaled corticosteroids; laMa, long-acting muscarinic antagonist.
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were still not well defined, and according to 61.5% an agree-
ment among experts was essential with respect to the possible 
coexistence of asthma and COPD criteria in the same patient, 
due to possible future therapeutic consequences. In this sense, 
76.9% were of the opinion that the ACOS criteria defined by 
a group of Spanish experts in 2012 should be validated, and 
34.8% and 30.8% partially agreed with this or were equi-
distant between agreement and disagreement, respectively. 
Up to 57.7% considered that diagnostic assessment of the 
component “asthma” was insufficient with these criteria, 
since it did not include nonallergic patients with asthma, and 
61.5% had the opinion that the criteria should be redefined 
in depth to include this aspect.
The criteria considered to be the most adequate for the 
diagnosis of ACOS were a previous history of asthma (88.5%), 
a history of smoking (73.1%), and postbronchodilator FEV
1
/
forced vital capacity (FVC) ,0.7 (69.2%) (Figure 1). 
Elevated Fraction of nitric oxide in exhaled air (FeNO) and 
a history of atopy were not considered to be adequate crite-
ria by 53.8% (both). Of the participants, 69.2% considered 
smoking to be important in that ACOS is basically composed 
of smoking asthmatic patients, and 80.8% agreed that the 
Spanish ACOS criteria had contributed to disseminating the 
recognition of ACOS.
With regard to treatment, 88.5% stated that ACOS 
required differentiated treatment, with 96.2% considering that 
first-line treatment of very severe ACOS should include long-
acting β
2
-agonists (LABAs)/inhaled corticosteroids (ICS) + 
long-acting muscarinic antagonists (LAMAs). Only 61.5% 
described this treatment as the first choice in the case of severe 
poorly controlled asthma and chronic airway obstruction.
Up to 73.1% said they agreed that the criteria of mixed 
phenotype should not differ for pneumology and primary 
care, and according to 50% the diagnostic and therapeutic 
evaluation of patients with ACOS should be made by 
pulmonologists. The remaining questions and responses to 
the questionnaire are shown in Table 1.
Phase 2: structured debate
During the phase 2 meeting, some of the statements included 
in the questionnaire were introduced into the structured dis-
cussion. The main points of discussion were as follows.
Definition of ACOS in the GINA–GOLD document
With regard to the definition of ACOS included in the GINA–
GOLD document,16 the participants concluded that this defi-
nition was very general and not very precise, although it did 
recognize ACOS and could be used as a starting point.
Diagnostic criteria of aCOs
The classification of importance and applicability of diag-
nostic criteria for ACOS in respiratory clinics and primary 
care are presented in Table 2. The criteria considered most 
important were first eosinophilia in sputum (80.8%), fol-
lowed by a very positive bronchodilator test (increase in 
FEV
1
 $15% and $400 mL compared to basal values) 
(69.2%) and a history of asthma before the age of 40 years 
(65.4%). Fe
NO
 values were considered important by 53.8% 
of the participants.
More than 65% of the specialists thought the most appli-
cable criterion was a very positive bronchodilator test, while 
a history of asthma and eosinophilia in blood were consid-
ered the more applicable criteria in primary care. The least 
applicable tests in primary care were eosinophilia in sputum, 
elevated Fe
NO
 levels, and positive skin and methacholine 
tests. The criteria least assessed were seasonal or increased 
variability of symptoms, positive skin tests, variability in 
maximum expiratory flow .20%, reversibility in the current 
Figure 1 Criteria preferred by the participants for the diagnosis of asthma–COPD overlap syndrome.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FenO, fraction of nitric oxide in exhaled air.
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
? ?? ?? ??
????????
???? ????
???? ????
????????
???? ????
?????????????
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1326
Miravitlles et al
Table 2 Classification of the importance of the criteria and applicability in specialized and primary care
Very important criteria Important criteria Less important criteria
Specialized care
Very applicable Very positive bronchodilator test (increase in FeV1 
$15% and $400 ml compared to basal value)
Previous history of asthma before 40 years of age
Positive bronchodilator test 
on two or more occasions
Blood eosinophilia
Positive bronchodilator test
Family history of atopy  
and/or asthma
Quite applicable elevated FenO Total Ige
Positive methacholine test
history of atopy
rhinitis of any type
Positive skin tests
not very applicable eosinophilia in sputum
Positive oral corticosteroid test
Increased or seasonal 
variability of symptoms
Variability of peak flow 
.20%
Primary care
Very applicable Previous history of asthma before 40 years of age eosinophilia in blood
Quite applicable Very positive bronchodilator test rhinitis of any type
elevated total Ige
Personal history of atopy
Family history of asthma  
and/or atopy
not very applicable eosinophilia in sputum
elevated FenO
Positive oral corticosteroid test
Positive bronchodilator test 
on two or more occasions
Positive methacholine test
Increased or seasonal 
variability of symptoms
Positive skin tests
Variability in peak flow .20%
Positive bronchodilator test
Notes: The “very applicable” criteria were considered as such by more than 65% of the panel. The “quite applicable” criteria were considered as such by 50%–65%, and the 
“not very applicable” were considered as such by less than 50% of the panel. Very positive bronchodilator test means an increase in FeV1$15% and $400 ml compared to 
basal value. Positive bronchodilator test means an increase in FeV1 $12% and $200 ml compared to basal value.
Abbreviations: FeV1, forced expiratory volume in 1 second; FenO, fraction of nitric oxide in exhaled air.
bronchodilator test, and a family history of asthma and/or 
atopy. The presence of rhinitis was considered important and 
applicable both in primary care and pulmonology clinics.
Treatment of aCOs
The debate about treatment was centered around three clinical 
scenarios (Table 3). The first case was a 62-year-old female ex-
smoker with dyspnea, postbronchodilator FEV
1
/FVC =0.61, a 
positive bronchodilator test, and without exacerbations. The 
most frequent diagnosis was asthma followed by ACOS. The 
main recommendation for therapy was LABA/ICS, although 
some participants suggested LAMA alone or combined with 
LABA, considering that she was a nonexacerbator with 
moderate COPD. For second-line therapy, the panel agreed 
on triple-therapy LAMA + LABA/ICS.
The second case was a 71-year-old male heavy smoker 
with a previous diagnosis of asthma, frequent exacerba-
tions, postbronchodilator FEV
1
/FVC =0.52, and a negative 
bronchodilator test. The majority of the panel agreed on the 
diagnosis of ACOS, although the possibility of COPD was 
also considered. The main treatment option was LABA/ICS, 
and some participants suggested triple therapy as the initial 
treatment. The second option was triple therapy with the 
possible addition of roflumilast.
The third case was a 68-year-old male ten-cigarettes/day 
smoker, diagnosed with asthma but without any respiratory 
treatment, who presented an exacerbation with purulent 
sputum. Postbronchodilator FEV
1
/FVC was 0.68, and a 
positive bronchodilator test showed an increase in FEV
1
 
of 312 mL and 14%. The main diagnosis was ACOS, with 
some participants suggesting a diagnosis of asthma. The first 
choice of treatment was LABA/ICS with an antibiotic for 
the exacerbation, while the second choice was triple therapy 
with LAMA + LABA/ICS.
Future investigation
Of all the proposals made, those with the greatest consensus 
were actions to be carried out within the setting of investiga-
tion using longitudinal, population studies, and clinical trials 
(73%) to allow a more robust definition of ACOS to be made, 
as well as the possibility of more precisely identifying these 
patients with biological markers (54%).
With regard to diffusion, more than half of the partici-
pants in the session agreed that a specific chapter on ACOS 
should be included in the guidelines of asthma and COPD. 
In addition, activities should be conducted with the clinicians 
involved in their diagnosis and treatment, whether these be 
primary care physicians or not, with the aim of detecting 
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ACOS or specialists elaborating a useful consensus for pri-
mary and specialized care.
Discussion
The existence of patients who fulfill the criteria for COPD – 
adult smokers with respiratory symptoms and postbroncho-
dilator FEV
1
/FVC ,0.7 – and who present characteristics 
of asthma, such as high reversibility of airflow, signs of 
bronchial and systemic eosinophilic inflammation, history 
of atopy, or even a previous diagnosis of asthma before the 
age of 40 years, is widely recognized. In a study in primary 
care, the participating physicians had difficulties in diagnos-
ing asthma or COPD in 19% of adult patients with respira-
tory symptoms taking respiratory medications, because they 
shared characteristics of both diseases.18 Recognition of 
the existence of patients who share characteristics of more 
than one chronic obstructive respiratory disease is not new. 
In 1958, the Ciba Symposium had already described individu-
als with asthma and chronic bronchitis or emphysema,19 and 
the American Thoracic Society COPD guidelines published 
in 1995 included a Venn diagram with the overlap of asthma 
and chronic bronchitis, emphysema, or both.20 However, dur-
ing the last 15 years and until very recently, the treatment of 
COPD has been managed exclusively by the degree of airflow 
obstruction and the presence of exacerbations.21 The concepts 
of phenotypes and endotypes in asthma22 and the results of 
large studies in COPD, such as ECLIPSE,23,24 have stimulated 
the interest in the concept of phenotypes in COPD.25 Among 
these phenotypes, ACOS has attracted increasing interest, 
due to its prevalence, prognosis, and specific treatment.26 In 
our survey, more than 80% of asthma and COPD specialists 
accepted the existence of ACOS as a particular subgroup of 
adult patients with chronic airflow limitation.
Despite the interest in ACOS, there are no universally 
accepted criteria for diagnosis. Up to 81% of the participants 
in our survey agreed that diagnostic criteria for ACOS were not 
yet well defined. In 2012, a group of COPD experts proposed 
diagnostic criteria for ACOS in COPD.12 These criteria were 
1) major criteria of very positive bronchodilator response 
(.400 mL and .15% in FEV
1
), sputum eosinophilia, or previ-
ous diagnosis of asthma, and 2) minor criteria of increased total 
serum IgE, previous history of atopy, or positive bronchodilator 
test (.200 mL and .12% in FEV
1
) on at least two occa-
sions. To be diagnosed with ACOS, a patient must fulfill two 
major or one major and two minor criteria. The new Finnish 
guidelines for the treatment of COPD proposed the same 
criteria for the diagnosis of ACOS as the Spanish guidelines, 
with the addition of an elevated Fe
NO
 higher than 50 parts per T
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billion as a major criterion and a peak flow follow-up typical 
for asthma as an additional minor criterion.15 The latest Czech 
Republic guidelines, published in 2013, also include ACOS 
with its own diagnostic criteria, similar to the Spanish recom-
mendations.14 These are quite restrictive criteria, and represent 
a very conservative approach until more evidence about the 
characterization of ACOS becomes available from large clinical 
trials or prospective studies. In fact, two recent studies in Spain 
using the previous criteria identified only between 5% and 
6% of patients fulfilling the criteria for ACOS in patients with 
smoking-related COPD.27,28 This percentage is clearly below 
the expected number of individuals sharing the characteristics 
of asthma and COPD, according to epidemiological data. In 
fact, only 34.6% of the specialists surveyed were in agreement 
with the Spanish criteria, and 30.8% were in an intermediate 
position between agreement and disagreement. The main aspect 
highlighted by 76.9% of the specialists was that these criteria 
had to be validated in prospective studies.
In 2014, GINA and GOLD published a joint document 
on ACOS.16 ACOS was defined as the presence of persistent 
airflow limitation with several features usually associated with 
asthma and several features usually associated with COPD. 
The document presents the characteristics of asthma and 
COPD listed separately and suggests that ACOS may be the 
diagnosis when a similar number of features of asthma and 
COPD are identified in a given patient. The opinion of most of 
the group was that this definition was imprecise. In particular, 
the GINA–GOLD criteria included postbronchodilator FEV
1
/
FVC ,0.7 and significant exposure to smoking as two more 
on the list of possible criteria. However, a history of smoking 
exposure and airflow obstruction were considered necessary 
for the diagnosis of ACOS by 73.1% and 69.2% of the par-
ticipants. A recent population-based study on phenotypes of 
airway disease performed in New Zealand identified a group 
of ACOS individuals by cluster analysis, and all were smokers 
or ex-smokers with chronic airflow obstruction.29 In fact, 
without smoking exposure and/or chronic airflow obstruc-
tion, the diagnosis can only be asthma, but ACOS cannot be 
accepted without evidence of COPD.
Regarding the diagnostic criteria, in a patient with COPD, 
those considered to be more important for the diagnosis of 
ACOS were a very positive bronchodilator test, a previous 
history of asthma before the age of 40 years, sputum eosino-
philia, high Fe
NO
, and a positive test for oral corticosteroids. 
This last test consists of the administration of 0.5 mg/kg of 
prednisone during 2–3 weeks, and is considered positive if 
there is an increase in FEV
1
 superior to 200 mL and 12%. Among 
those considered important were a positive bronchodilator test 
on at least two occasions, increased blood eosinophilia, high 
total IgE, a positive methacholine-challenge test, a personal 
history of atopy, and any type of rhinitis. Most of these 
criteria had already been described in the previous Spanish 
consensus, except for rhinitis, the methacholine-challenge 
test, elevated Fe
NO
, and the positive oral corticosteroid test.12 
However, the participants could not agree on any particular 
requirement in terms of number or preference of criteria for 
the diagnosis of ACOS. Another important aspect was that 
some of the criteria were considered not feasible for routine 
clinical practice, as is the case with sputum eosinophilia, the 
oral corticosteroid test, and Fe
NO
 determination in the context 
of primary care. It was agreed that until validation studies are 
developed, the clinician should consider ACOS in a patient 
with COPD and the presence of some of the aforementioned 
criteria. In particular, 88.5% considered a previous history of 
asthma before the age of 40 years in a patient with COPD to 
be very indicative of ACOS. With only this criterion, in the 
COPDGene study, Hardin et al found that 13% of subjects with 
COPD had ACOS.7 In the PLATINO study performed in Latin 
America, a prevalence of 11.6% was described using a post-
bronchodilator FEV
1
/FVC ,0.7 and the diagnosis of asthma 
as ACOS criteria.30 In the Spanish EPISCAN epidemiological 
study, including patients with COPD and a previous diagnosis 
of asthma before the age of 40 years, the prevalence of ACOS 
observed among the COPD population was 17.4%.8 Similarly, 
in a large study on 3,125 COPD patients from primary and 
secondary care, 15.9% were classified as ACOS due to a 
previous diagnosis of asthma.31 It would be very relevant to 
investigate if the previous diagnosis of asthma by itself could 
identify the population with ACOS in COPD.
Patients with ACOS have been systematically excluded 
from both COPD and asthma pharmacological trials for not 
being “pure” subjects. As a consequence, there is no clear 
information about the response of these patients to most of 
the current pharmacological therapies. The only clinical 
trial performed to date in patients with ACOS studied the 
spirometric effects of tiotropium in individuals with con-
comitant COPD and asthma. Improvements in lung function 
and a reduction in rescue medication were observed with 
tiotropium.32 However, the main interest in differentiating 
ACOS from COPD lies in the different response to ICS. 
In the three cases presented to the panel, the first option of 
treatment chosen was the combination of LABA and ICS. 
This is the first option described in the Spanish guidelines for 
COPD,13 as in those of the Canadians,33 Japanese,34 Finns,15 
and Czechs.14 The GINA–GOLD document also indicates 
that the default position in the case of ACOS should be to 
start treatment accordingly for asthma, and recommends the 
LABA/ICS combination with special attention to avoid the 
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use of LABAs in monotherapy.16 In our survey, 88.5% of the 
participants agreed that ACOS requires a different treatment 
compared to COPD, starting with LABA/ICS and stepping up 
to triple therapy (LABA/ICS + LAMA) in severe cases.
Finally, the majority of the participants were of the opinion 
that the diagnosis and assessment of ACOS should be done 
by the pulmonologist, but the follow-up can be shared with 
the primary care physician, and in particular 73.1% thought 
that the criteria for ACOS must be the same in primary and 
secondary care. Among the suggestions for future research, it 
was agreed that longitudinal multicenter studies are required 
to validate the diagnostic criteria and identify biomarkers of 
the disease. In addition, clinical trials are necessary to verify 
the response to treatments of this group of patients.
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